Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept with Rituximab in Rheumatoid Arthritis
NCT00664521Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2008
- Primary completion
- Oct 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rituximab Plus Atacicept with Rituximab Plus Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Percentage of Participants With Immunoglobulin G Level Less Than 3 g/L at Week 64 and 2 more. Started Mar 2008; status: completed.
02
Drugs
atacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00664521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664521.